Asthma

Atrial Fibrillation

Autoimmune Diseases

Biologics

Biosimilars

Blood Cancer

Breast Cancer

COVID-19

Cardiovascular Diseases

Depression

Dermatology

Diabetes

Digital Health

Drug Coverage

Eyecare

Friedreich Ataxia

Gene Therapy

Graft Versus Host Disease

Heart Failure

Hemophilia

Hypertrophic Cardiomyopathy (HCM)

Leukemia and Lymphoma

Liver Disease

Lung Cancer

Mental Health

Multiple Sclerosis

NSCLC

Neonatal Care

Obstetrics-Gynecology & Women's Health

Oncology

Opioids

Pain

Pediatrics

Plaque Psoriasis

Population Health

Post-Acute Care

Prescription Digital Therapeutics

Pulmonary Arterial Hypertension

Reproductive Health

Respiratory Conditions

Safety & Recalls

Sleep Disorders

Solid Tumors

Spinal Muscular Atrophy

Substance Use Disorder

The Improving Patient Access Podcast

Type I Diabetes

Type II Inflammation

Ulcerative Colitis

Urology

Urothelial Carcinoma

Vaccines

Vaccines: 2023 Year in Review

Women's Health

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Formulary Watch Spotlights

Supplements And Featured Publications

Events

2024 PBMI Annual National Conference

PBMI MAP

Virtual Events

CME/CE

Resources

Emerging Leaders

PBM Leaders

Subscribe

Articles

One area of interest is whether ketogenic diets, which are high in fat and low in carbohydrates, might be helpful to people with treatment-resistant depression. 

Researchers Explore Connections Between Diet, Treatment-Resistant Depression

Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.

The 2024 increase is the same as last year's increase for family coverage. The foundation’s annual survey of employer health benefits also found that only 18% of large employers (200 employees are more) are covering the GLP-1 weight loss drugs.

Premiums for Employer-based Health Insurance Increased by 7% in 2024, Says KFF Report

If approved, elinzanetant would be another non-hormonal option for menopausal women seeking hot flash relief. 

FDA Accepts NDA for Menopause Drug, Elinzanetant

Apitegromab works by targeting a protein called myostatin that limits muscle growth and is designed to be used alongside existing spinal muscular atrophy (SMA) treatments.

Apitegromab Shows ‘Robust’ Motor Improvement in Phase 3 SMA Trial Update

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive

Facebook

LinkedIn

Resource Centers

Eye Care

Spotlight

ASRS

AIDS Conference

ATS 

AHIP

Asembia’s Specialty Pharmacy Summit

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

1rem

Clinical

Less than a quarter of menopausal women have their menopause symptoms entered into their charts at primary care visits, resulting in missed opportunities for timely treatment. 

Menopause Care Gaps Exist in Primary Care 

Insulin resistance reduction was seen in trials using both estrogen and estrogen plus progesterone, a meta-analysis of 17 studies reveal. 

Hormone Therapy Reduced Insulin Resistance in Postmenopausal Women, Study Shows

Insight into nocturnal hot flash timing could provide clues about heart disease risk in perimenopausal women. 

More Hot Flashes Occur in Second Half of Night, Preliminary Data Shows

Women with disadvantaged backgrounds may also benefit more than women with a higher socioeconomic status, study results show.

Postmenopausal Women Who Use Hormone Therapy Biologically Younger 

Women's Health

Latest News